FNT
ABBV icon

First Nebraska Trust’s AbbVie ABBV Stock Holding History

First Nebraska Trust’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.55M Sell
7,118
-35
-0.5% -$7.76K 0.14% 87
2025
Q4 		$1.63M Buy
7,153
+850
+13% +$194K 0.15% 86
2025
Q3 		$1.46M Hold
6,303
– – 0.13% 89
2025
Q2 		$1.13M Buy
6,303
+200
+3% +$37.2K 0.11% 99
2025
Q1 		$1.28M Buy
6,103
+190
+3% +$36.9K 0.13% 93
2024
Q4 		$1.05M Hold
5,913
– – 0.1% 98
2024
Q3 		$1.17M Sell
5,913
-120
-2% -$22.4K 0.11% 97
2024
Q2 		$1.03M Sell
6,033
-40
-0.7% -$6.63K 0.11% 98
2024
Q1 		$1.11M Buy
6,073
+245
+4% +$42.2K 0.11% 93
2023
Q4 		$903K Buy
5,828
+20
+0.3% +$2.92K 0.1% 96
2023
Q3 		$866K Hold
5,808
– – 0.11% 91
2023
Q2 		$783K Buy
5,808
+100
+2% +$14.7K 0.09% 94
2023
Q1 		$910K Buy
5,708
+120
+2% +$18.3K 0.11% 87
2022
Q4 		$903K Buy
5,588
+195
+4% +$29.9K 0.12% 88
2022
Q3 		$724K Sell
5,393
-7
-0.1% -$1K 0.1% 90
2022
Q2 		$827K Sell
5,400
-30
-0.6% -$4.58K 0.11% 89
2022
Q1 		$880K Sell
5,430
-1,500
-22% -$218K 0.1% 91
2021
Q4 		$938K Sell
6,930
-143
-2% -$16.9K 0.11% 85
2021
Q3 		$763K Buy
7,073
+150
+2% +$17.1K 0.1% 90
2021
Q2 		$780K Buy
6,923
+150
+2% +$16.9K 0.1% 90
2021
Q1 		$733K Sell
6,773
-348
-5% -$37.2K 0.1% 94
2020
Q4 		$763K Sell
7,121
-329
-4% -$31.6K 0.11% 87
2020
Q3 		$653K Hold
7,450
– – 0.11% 91
2020
Q2 		$731K Buy
7,450
+317
+4% +$27.9K 0.14% 85
2020
Q1 		$543K Buy
+7,133
New +$608K 0.12% 87
2014
Q2 		– Sell
-4,576
Closed -$235K – 103
2014
Q1 		$235K Sell
4,576
-375
-8% -$19K 0.07% 81
2013
Q4 		$261K Hold
4,951
– – 0.08% 81
2013
Q3 		$221K Buy
+4,951
New +$219K 0.08% 83

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Nebraska Trust's ABBV Position: Q1 2026 in Review

First Nebraska Trust reduced its AbbVie (ABBV) stake by 0.49% in Q1 2026, selling an estimated $7.76K and leaving 7,118 shares worth $1.55M. The position accounts for 0.14% of the portfolio, ranked #87.

First Nebraska Trust first reported a position in ABBV in Q3 2013 and has held it in 28 quarters since. The position peaked at $1.63M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • First Nebraska Trust held 7,118 shares of AbbVie worth $1.55M as of Q1 2026.
  • First Nebraska Trust sold 35 AbbVie shares in Q1 2026, an estimated $7.76K.
  • AbbVie made up 0.14% of First Nebraska Trust's portfolio in Q1 2026, its #87 holding.
  • First Nebraska Trust first reported a position in AbbVie in Q3 2013 and has held it in 28 quarters since.
  • First Nebraska Trust's AbbVie position peaked at $1.63M in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on First Nebraska Trust's 13F filing for Q1 2026, filed 1 Jun 2026.